Table 2 The patient outcomes in MP group and control group
|  | MP group (n = 57) | Control group (n = 54) | P value |
|---|---|---|---|
Follow up duration (month, medium (range)) | 32 (3-140) | 29 (3-133) | 0.922 |
Serum creatinine (median (IQR), μmol/L) | 383.0 (233.5-548.0) | 700.0 (436.8-830.5) | <0.01 |
eGFR (median (IQR), ml/min/1.73 m2) | 13.0 (8.0-23.8) | 7.1(5.3-9.8) | <0.01 |
Death | 11, 19.3% | 20, 37.0% | 0.056 |
 Infections | 9 | 13 |  |
 Cardiovascular diseases | 1 | 3 |  |
 Hemorrhage | 0 | 3 |  |
 Cancer | 1 | 1 |  |
Maintaining dialysis | 21, 36.8% | 29, 53.7% | 0.088 |
Dialysis independent | 21, 36.8% | 4, 7.4% | <0.01 |
 CKD-II | 1 | 0 |  |
 CKD-III | 4 | 2 |  |
 CKD-IV | 7 | 0 |  |
 CKD-V | 9 | 2 |  |
Lost | 4, 7.0% | 1, 1.3% | 0.364 |